The immune checkpoint marker PD-L1 has been shown to increase in anaplastic meningiomas [49], suggesting that higher-grade tumours harbour a more immunosuppressive tumour microenvironment [50], although immune therapy targeting PD-L1 in meningiomas may be limited due to expression levels [51,52]. Here, CD274 is linked to meningioma.